Compare DCGO & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DCGO | PMVP |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Managed Health Care | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.5M | 66.1M |
| IPO Year | 2020 | 2020 |
| Metric | DCGO | PMVP |
|---|---|---|
| Price | $0.41 | $1.32 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $2.38 | N/A |
| AVG Volume (30 Days) | ★ 734.8K | 305.0K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $322,196,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.77 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.42 | $1.02 |
| 52 Week High | $1.73 | $1.88 |
| Indicator | DCGO | PMVP |
|---|---|---|
| Relative Strength Index (RSI) | 31.80 | 60.30 |
| Support Level | N/A | $1.04 |
| Resistance Level | $0.67 | $1.49 |
| Average True Range (ATR) | 0.05 | 0.07 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 2.66 | 95.16 |
DocGo Inc is a provider of last-mile mobile health services and integrated medical mobility solutions. The company uses its care delivery platform to provide mobile health services, virtual care management, and ambulance services. It has two reporting segments: Mobile Health Services and Transportation Services. A majority of its revenue is generated from the Mobile Health Services segment, which includes various healthcare services performed at homes, offices, and other locations and event services such as on-site healthcare support at sporting events and concerts. Geographically, the company generates a majority of its revenue from the United States and the rest from the United Kingdom.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.